Article
Complex interactions between the microbiome and cancer immune therapy
17 Sept 2019
Abstract excerpt
Immuno-oncology has rapidly grown in the last thirty years, and immunotherapeutic agents are now approved to treat many disparate cancers. Immune checkpoint inhibitors (ICIs) are employed to augment cytotoxic anti-cancer activity by inhibiting negative regulatory elements of the immune system. Modulating the immune system to target neoplasms has improved survivability of numerous cancers in many individuals, but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
